AVCRF Avricore Health Inc. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1355736 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY33.7%
TTM net income YoY4.6%
TTM EPS YoY0.0%
Revenue 3-yr CAGR236.0%
Net income 3-yr CAGR—
Margins
Gross margin40.4%
Operating margin—
Net margin-14.4%
FCF margin17.7%
EBITDA margin—
Returns
ROE-33.6%
ROA-27.7%
ROIC (approx.)—
Asset turnover1.93x
Leverage & solvency
Liabilities / assets14.4%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.50x
Accruals ratio-69.2%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 4.66M | 3.48M |
| Cost of revenue | 2.91M | 2.28M |
| Gross profit | 1.88M | 1.20M |
| SG&A expense | 409,398 | 339,369 |
| Pretax income | 129,001 | -693,253 |
| Net income | -668,977 | -701,215 |
| EPS (basic) | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 100.31M | 99.56M |
| Balance sheet | ||
| Cash & equivalents | 1.13M | 276,571 |
| Receivables | 419,587 | 427,689 |
| Inventory | 507 | 20,676 |
| Current assets | 1.58M | 773,561 |
| PP&E, netmay include right-of-use assets (IFRS) | 656,441 | 1.72M |
| Total assets | 2.30M | 2.54M |
| Total liabilities | 330,817 | 529,218 |
| Shareholders' equity | 1.97M | 2.01M |
| Cash flow statement | ||
| Operating cash flow | 1.00M | 660,403 |
| Capital expenditure | 181,094 | 1.02M |
| Free cash flow | 823,521 | -361,168 |
| Investing cash flow | -205,347 | -1.05M |
| Financing cash flow | 56,600 | 42,500 |
| Depreciation & amortization | 3,137 | 2,347 |
| Stock-based compensation | 541,164 | 703,612 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.